The rising prevalence of musculoskeletal diseases leads to increasing demand for allografts. With the growing population, the pressure on the healthcare system is rising for the proper treatment proportionally surges the need for care, services, and technologies to prevent and treat musculoskeletal conditions like sarcopenia, osteoporosis, osteopenia, and other musculoskeletal complications. Many older adults are more prone to these conditions leading to fragile bones and joints. In such patients, allografts are used to provide them with immediate and efficient benefits associated with their bodies. This increasing age and rising prevalence of chronic diseases, including musculoskeletal conditions, is increasing the demand for care, services, and technologies to prevent and treat these conditions in old age. Therefore, the demand for foot and ankle allografts is expected to rise for treatment in the region's healthcare system and across the globe.
Access Full Report @ https://www.databridgemarketresearch.com/reports/asia-pacific-foot-ankle-allograft-market
Data Bridge Market Research analyses that the Asia-Pacific Foot and Ankle Allograft Market is expected to grow at a CAGR of 8.0% from 2022 to 2029 and is expected to reach USD 256.59 million by 2029. The rise in the prevalence of musculoskeletal disorders is expected to propel the growth of the market.
Key Findings of the Study
Increase in Prevalence of Musculoskeletal Disorder
Musculoskeletal disorders majorly affect the patient's locomotor system, which includes muscles, bones, joints, and associated tissues such as tendons and ligaments. Musculoskeletal disorders range from short-lived conditions like fractures, sprains, and strains to lifelong conditions allied with ongoing pain and disability. The most common and disabling musculoskeletal disorders include fractures associated with bone fragility, osteoarthritis, injuries, and systemic inflammatory conditions such as rheumatoid arthritis. Allografts have been used to correct these deformities or fill bone defects secondary to trauma, osteochondral lesions, or intercalary arthrodesis.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2015-2019)
|
|
Quantitative Units
|
Revenue in USD Million
|
|
Segments Covered
|
Product Type (Allograft Wedges, Allograft Tendons, Allograft Acellular Dermal Matrix, Cartilage Allograft Matrix, Skin Allografts, and Amniotic Membranes), Surgery Type (Orthopaedic Reconstruction, Cartilage Restoration, Soft Tissue Tendon & Ligament Repair, and Wound Care), Procedure (Midfoot Procedures and Hindfoot Procedures), End User (Hospitals, Orthopedic Clinics, Ambulatory Surgical Centres, Academic and Research Institutes, and Other End Users)
|
|
Countries Covered
|
China, Japan, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines and Rest of Asia-Pacific
|
|
Market Players Covered
|
LifeNet Health (U.S.), Zimmer Biomet (U.S.), Johnson and Johnson services Inc (U.S.), Integra LifeSciences (U.S.), CONMED Corporation. (U.S.), Stryker (U.S.), Globus Medical (U.S.), Smith –Nephew (U.S.), Institut Straumann AG (Switzerland), Arthrex, Inc. (Germany), Organogenesis Inc. (U.S.), among others
|
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Segment Analysis:
Asia-Pacific foot and ankle allografts market is segmented on the basis of product type, surgery type, procedure and end user.
- On the basis of product type, the Asia-Pacific foot and ankle allografts market is segmented into allograft wedges, allograft tendons, allograft, acellular dermal matrix, cartilage allograft matrix, skin allografts, and Amniotic Membranes.
In 2022, allograft wedges segment is the dominant segment in Asia-Pacific foot and ankle allografts market
In 2022, allograft wedges segment is the dominant segment in Asia-Pacific foot and ankle allografts market holding a market share of 37.03% as of increasing advancement in the technology.
- On the basis of surgery type, the Asia-Pacific foot and ankle allografts market is segmented into orthopedic reconstruction, cartilage restoration, soft tissue tendon & ligament repair and wound care. In 2022, orthopedic reconstruction segment is the dominant segment in Asia-Pacific foot and ankle allografts market holding a market share of 31.80%.
- On the basis of procedure, the Asia-Pacific foot and ankle allografts market is segmented into midfoot procedures and hindfoot procedures. In 2022, midfoot procedures segment is the dominant segment in Asia-Pacific foot and ankle allografts market holding a market share of 66.92%.
- On the basis of end user, the Asia-Pacific foot and ankle allografts market is segmented into hospitals, orthopedic clinics, ambulatory surgical centers, academic and research institutes and other end users.
In 2022, the hospitals segment is the dominant segment in Asia-Pacific foot and ankle allografts market
In 2022, hospitals segment is the dominant segment in Asia-Pacific foot and ankle allografts market holding a market share of 52.07% due to the increasing patient population in hospitals.
Major Players
Data Bridge Market Research recognizes the following companies as the major market players in the Asia-Pacific foot and ankle allograft market. LifeNet Health (U.S.), Zimmer Biomet (U.S.), Johnson and Johnson services Inc (U.S.), Integra LifeSciences (U.S.), CONMED Corporation. (U.S.), Stryker (U.S.), Globus Medical (U.S.), Smith –Nephew (U.S.), Institut Straumann AG (Switzerland), Arthrex, Inc. (Germany), Organogenesis Inc. (U.S.)
Market Developments
- In March 2022, Lifenet Health announce that they will be showcasing their innovative all-human research solutions at SOT ToxExpo which has increased company’s customer’s engagement.
- In March 2022, Zimmer Biomet announced that they have sign a multiyear agreement with Biocomposites to exclusively distribute genex Bone Graft Substitute with its new mixing system and delivery options in the U.S. orthopaedic market. This will help company to increase their revenue and sales.
- In August 2021, Johnson & Johnson Services Inc., announced that their company DePuy Synthes has featured their new products and technology solutions shaping new standards of care for modern day orthopaedics during the American Academy of Orthopaedic Surgeons (AAOS) annual meeting. This has helped the company to gain more customers and sales.
In July 2021, Integra LifeSciences announced the positive clinical outcomes for PriMatrix Dermal Repair Scaffold for the management of hard to heal diabetic foot ulcers (DFUs). This positives results have increased company’s sales and customer’s engagement.
Regional Analysis
Geographically, the country covered in the Asia-Pacific foot and ankle allograft market report are China, Japan, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines and Rest of Asia-Pacific.
As per Data Bridge Market Research analysis:
China is the dominant and the fastest growing country in the Asia-Pacific foot and ankle allograft market
China is the dominant and fastest growing country in the Asia-Pacific foot and ankle allograft market due to rising geriatric population who are at greater risk of injuries and rising prevalence of musculoskeletal disorders and athletic injuries.
For more detailed information about the Asia-Pacific foot and ankle allograft market, click here – https://www.databridgemarketresearch.com/reports/asia-pacific-foot-ankle-allograft-market
